Adjuvant therapy for renal cell carcinoma, finally a new standard?

Alex Renner, Carlos Rojas, Annerleim Walton-Diaz, Mauricio Burotto*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.

Original languageEnglish
Article number926661
JournalFrontiers in Oncology
StatePublished - 29 Sep 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2022 Renner, Rojas, Walton-Diaz and Burotto.


  • adjuvant
  • immunotherapy
  • pembrolizumab
  • renal cell carcinoma
  • tyrosine kinase inhibitions (TKIs) therapy


Dive into the research topics of 'Adjuvant therapy for renal cell carcinoma, finally a new standard?'. Together they form a unique fingerprint.

Cite this